CARVYKTI
The FDA has recognized CARVYKTI for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.
Manufacturers of CAR-T cell therapies, oncology regulatory specialists, and clinical departments managing late-stage multiple myeloma treatments.
This emphasizes a specific therapeutic niche for CAR-T intervention in patients who have exhausted standard-of-care options, including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies. It suggests a stringent regulatory requirement for documentation of treatment history prior to administration.
Regulatory teams should ensure all labeling and promotional materials align with the specified prior-line therapy requirements. Clinical and pharmacovigilance teams should monitor for adverse events specifically within this heavily pre-treated patient population.
For the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
Open in openFDA / FDA.gov